NASDAQ:DMTK - DermTech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.00
  • Forecasted Upside: 98.66 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$32.72
▼ -1.91 (-5.52%)

This chart shows the closing price for DMTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DermTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMTK

Analyst Price Target is $65.00
▲ +98.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DermTech in the last 3 months. The average price target is $65.00, with a high forecast of $79.00 and a low forecast of $53.00. The average price target represents a 98.66% upside from the last price of $32.72.

This chart shows the closing price for DMTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in DermTech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2021OppenheimerReiterated RatingBuy$58.00High
5/3/2021BTIG ResearchInitiated CoverageBuy$53.00Medium
3/5/2021Craig HallumBoost Price TargetBuy$49.00 ➝ $70.00High
3/4/2021OppenheimerReiterated RatingBuy$58.00Medium
2/11/2021Lake Street CapitalBoost Price TargetBuy$52.00 ➝ $79.00Low
1/21/2021OppenheimerInitiated CoverageOutperform$53.00High
1/20/2021Craig HallumBoost Price TargetBuy$23.00 ➝ $49.00High
12/14/2020Craig HallumInitiated CoverageBuy$23.00High
10/29/2020William BlairInitiated CoverageOutperformHigh
9/11/2020Brookline Capital ManagementInitiated CoverageBuyHigh
9/10/2020CowenInitiated CoverageOutperform$20.00High
5/1/2020Lake Street CapitalReiterated RatingBuy$24.00High
3/17/2020Lake Street CapitalReiterated RatingBuy$15.00 ➝ $24.00Low
3/11/2020Lake Street CapitalBoost Price TargetBuy$15.00 ➝ $24.00Medium
12/5/2019Lake Street CapitalInitiated CoverageBuy$15.00High
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/29/2021
  • 8 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
9/28/2021

Current Sentiment

  • 8 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

DermTech logo
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.
Read More

Today's Range

Now: $32.72
Low: $32.56
High: $33.69

50 Day Range

MA: $35.22
Low: $32.16
High: $38.45

52 Week Range

Now: $32.72
Low: $10.20
High: $84.49

Volume

8,024 shs

Average Volume

1,072,918 shs

Market Capitalization

$968.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of DermTech?

The following Wall Street research analysts have issued research reports on DermTech in the last twelve months: BTIG Research, Craig Hallum, Lake Street Capital, Oppenheimer Holdings Inc., TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for DMTK.

What is the current price target for DermTech?

4 Wall Street analysts have set twelve-month price targets for DermTech in the last year. Their average twelve-month price target is $65.00, suggesting a possible upside of 98.7%. Lake Street Capital has the highest price target set, predicting DMTK will reach $79.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $53.00 for DermTech in the next year.
View the latest price targets for DMTK.

What is the current consensus analyst rating for DermTech?

DermTech currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DMTK will outperform the market and that investors should add to their positions of DermTech.
View the latest ratings for DMTK.

What other companies compete with DermTech?

How do I contact DermTech's investor relations team?

DermTech's physical mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company's listed phone number is (858) 450-4222 and its investor relations email address is [email protected] The official website for DermTech is www.dermtech.com.